Does the media refer more to CTMX or SRPT?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat CytomX Therapeutics' score of -0.65 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Sarepta Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to EDIT or SRPT?

In the previous week, Editas Medicine had 2 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 5 mentions for Editas Medicine and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat Editas Medicine's score of 0.64 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer SRPT or TGTX?

In the previous week, TG Therapeutics had 5 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 8 mentions for TG Therapeutics and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat TG Therapeutics' score of 0.88 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SRPT or ORKA?

In the previous week, Oruka Therapeutics had 2 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 5 mentions for Oruka Therapeutics and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat Oruka Therapeutics' score of 0.43 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oruka Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CGON or SRPT?

In the previous week, CG Oncology had 5 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 8 mentions for CG Oncology and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat CG Oncology's score of 0.62 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Sarepta Therapeutics (SRPT) Competitors

$18.79 -0.43 (-2.24%)

As of 08/21/2026 04:00 PM Eastern

Compare

SRPT vs. CTMX, EDIT, TGTX, ORKA, and CGON

Should you buy Sarepta Therapeutics stock or one of its competitors? Sarepta Therapeutics's main competitors and comparable companies include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), TG Therapeutics (TGTX), Oruka Therapeutics (ORKA), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sarepta Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

CytomX Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

CytomX Therapeutics currently has a consensus target price of $11.90, indicating a potential upside of 262.80%. Sarepta Therapeutics has a consensus target price of $25.06, indicating a potential upside of 33.36%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Sarepta Therapeutics	5 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.20

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, CytomX Therapeutics had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat CytomX Therapeutics' score of -0.65 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Sarepta Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CytomX Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	9.38	-$17.37M	-$0.50	N/A
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$2.90	N/A

Sarepta Therapeutics has a net margin of -13.48% compared to CytomX Therapeutics' net margin of -435.21%. Sarepta Therapeutics' return on equity of -1.60% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

Summary

CytomX Therapeutics and Sarepta Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Editas Medicine has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

Editas Medicine presently has a consensus target price of $5.50, indicating a potential upside of 76.85%. Sarepta Therapeutics has a consensus target price of $25.06, indicating a potential upside of 33.36%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities analysts plainly believe Editas Medicine is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Sarepta Therapeutics	5 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Editas Medicine had 2 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 5 mentions for Editas Medicine and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat Editas Medicine's score of 0.64 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Editas Medicine has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	11.79	-$160.06M	-$0.75	N/A
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$2.90	N/A

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sarepta Therapeutics has a net margin of -13.48% compared to Editas Medicine's net margin of -157.32%. Sarepta Therapeutics' return on equity of -1.60% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

Summary

Editas Medicine and Sarepta Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to TG Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, TG Therapeutics had 5 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 8 mentions for TG Therapeutics and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat TG Therapeutics' score of 0.88 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TG Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$2.90	N/A
TG Therapeutics	$616.29M	13.48	$447.18M	$2.74	19.81

Sarepta Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

TG Therapeutics has a net margin of 55.22% compared to Sarepta Therapeutics' net margin of -13.48%. TG Therapeutics' return on equity of 73.49% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
TG Therapeutics	55.22%	73.49%	34.14%

Sarepta Therapeutics currently has a consensus price target of $25.06, indicating a potential upside of 33.36%. TG Therapeutics has a consensus price target of $63.00, indicating a potential upside of 16.09%. Given Sarepta Therapeutics' higher probable upside, analysts clearly believe Sarepta Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	5 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.20
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

TG Therapeutics beats Sarepta Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Oruka Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, Oruka Therapeutics had 2 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 5 mentions for Oruka Therapeutics and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat Oruka Therapeutics' score of 0.43 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oruka Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$2.90	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Sarepta Therapeutics presently has a consensus price target of $25.06, indicating a potential upside of 33.36%. Oruka Therapeutics has a consensus price target of $134.30, indicating a potential upside of 24.40%. Given Sarepta Therapeutics' higher probable upside, equities research analysts clearly believe Sarepta Therapeutics is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	5 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.20
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Oruka Therapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Sarepta Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market.

Summary

Sarepta Therapeutics beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Sarepta Therapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

CG Oncology has higher earnings, but lower revenue than Sarepta Therapeutics. CG Oncology is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,751.08	-$160.99M	-$2.69	N/A
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$2.90	N/A

Sarepta Therapeutics has a net margin of -13.48% compared to CG Oncology's net margin of -3,602.68%. Sarepta Therapeutics' return on equity of -1.60% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, CG Oncology had 5 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 8 mentions for CG Oncology and 3 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.60 beat CG Oncology's score of 0.62 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

CG Oncology currently has a consensus price target of $83.18, indicating a potential upside of 4.22%. Sarepta Therapeutics has a consensus price target of $25.06, indicating a potential upside of 33.36%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sarepta Therapeutics	5 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Sarepta Therapeutics beats CG Oncology on 9 of the 15 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRPT vs. The Competition

Export

Metric	Sarepta Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.98B	$4.01B	$7.38B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-6.48	11.62	272.60	24.25
Price / Sales	0.90	1,334.43	623.26	100.86
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	1.30	16.80	13.05	6.20
Net Income	-$713.41M	-$12.50M	$3.47B	$348.59M
7 Day Performance	3.81%	3.29%	2.09%	0.08%
1 Month Performance	18.32%	8.23%	6.63%	3.88%
1 Year Performance	-7.07%	55.05%	25.01%	16.98%

Sarepta Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRPT Sarepta Therapeutics	3.7026 of 5 stars	$18.79 -2.2%	$25.06 +33.4%	-7.1%	$1.98B	$2.20B	N/A	1,372	Positive News Analyst Downgrade
CTMX CytomX Therapeutics	2.4662 of 5 stars	$3.45 +2.7%	$11.90 +244.9%	+54.7%	$732.14M	$76.20M	N/A	170	Analyst Downgrade
EDIT Editas Medicine	2.3588 of 5 stars	$2.84 +0.7%	$5.40 +90.1%	+11.1%	$433.10M	$40.52M	N/A	230	Analyst Forecast
TGTX TG Therapeutics	3.8453 of 5 stars	$49.28 +1.1%	$63.00 +27.8%	+84.3%	$7.46B	$616.29M	17.99	290	News Coverage Options Volume
ORKA Oruka Therapeutics	3.0953 of 5 stars	$112.66 +1.5%	$134.30 +19.2%	+599.2%	$7.35B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRPT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, TGTX, ORKA, and CGON

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Summary

How does Sarepta Therapeutics compare to TG Therapeutics?

Summary

How does Sarepta Therapeutics compare to Oruka Therapeutics?

Summary

How does Sarepta Therapeutics compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, TGTX, ORKA, and CGON

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Which has more risk and volatility, CTMX or SRPT?

Do analysts prefer CTMX or SRPT?

Do insiders & institutionals believe in CTMX or SRPT?

Does the media refer more to CTMX or SRPT?

Which has better valuation & earnings, CTMX or SRPT?

Is CTMX or SRPT more profitable?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Which has more volatility and risk, EDIT or SRPT?

Do analysts prefer EDIT or SRPT?

Does the media refer more to EDIT or SRPT?

Which has preferable valuation and earnings, EDIT or SRPT?

Do institutionals and insiders believe in EDIT or SRPT?

Is EDIT or SRPT more profitable?

Summary

How does Sarepta Therapeutics compare to TG Therapeutics?

Does the media prefer SRPT or TGTX?

Which has stronger valuation and earnings, SRPT or TGTX?

Which has more volatility & risk, SRPT or TGTX?

Is SRPT or TGTX more profitable?

Do analysts prefer SRPT or TGTX?

Do institutionals & insiders believe in SRPT or TGTX?

Summary

How does Sarepta Therapeutics compare to Oruka Therapeutics?

Does the media refer more to SRPT or ORKA?

Which has higher valuation and earnings, SRPT or ORKA?

Do analysts rate SRPT or ORKA?

Do insiders and institutionals hold more shares of SRPT or ORKA?

Is SRPT or ORKA more profitable?

Which has more risk and volatility, SRPT or ORKA?

Summary

How does Sarepta Therapeutics compare to CG Oncology?

Which has better valuation & earnings, CGON or SRPT?

Is CGON or SRPT more profitable?

Do institutionals & insiders believe in CGON or SRPT?

Does the media favor CGON or SRPT?

Which has more risk & volatility, CGON or SRPT?

Do analysts recommend CGON or SRPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools